Molecular Epidemiology and Antifungal Susceptibility Profile in Nakaseomyces glabrata Species Complex: A 5‐Year Countrywide Study
Maryam Salimi,Javad Javidnia,Leila Faeli,Azam Moslemi,Mohammad Taghi Hedayati,Iman Haghani,Seyed Reza Aghili,Maryam Moazeni,Parisa Badiee,Maryam Roudbari,Hossein Zarrinfar,Rasoul Mohammadi,Ensieh Lotfali,Sadegh Nouripour‐Sisakht,Seyedmojtaba Seyedmousavi,Tahereh Shokohi,Mahdi Abastabar
DOI: https://doi.org/10.1002/jcla.25042
IF: 3.124
2024-05-24
Journal of Clinical Laboratory Analysis
Abstract:Because of the increasing prevalence of azole resistance, the treatment of invasive Nakaseomyces glabrata infection is considered an important clinical challenge. To determine the source of fungal infection, drug susceptibility, geographical distribution, and any relationships between them, it is necessary and important to determine the genotype. The initial screening was performed by morphological characteristics on CHROMagar Candida. Each isolate was identified by targeting the D1/D2 rDNA using a multiplex‐PCR method. To validate the mPCR method and determine genetic diversity, the ITS‐rDNA region was randomly sequenced in 40 isolates. Maximum likelihood phylogeny tree based on DNA sequence data was constructed using DNA sequence data for the ITS‐rDNA region from 40 isolates of N. glabrata sensu stricto. The present study revealed the presence of eight distinct ITS clades among the isolates. The predominant clades identified were Clades VII, V, and IV. The widest MIC ranges were observed for voriconazole and isavuconazole, whereas the narrowest ranges were seen with itraconazole and amphotericin B. Background The current study aimed to identify Iranian Nakaseomyces (Candida) glabrata complex species in the clinical isolates and determine their antifungal susceptibility profile. Methods In total, 320 N. glabrata clinical isolates were collected from patients hospitalized in different geographical regions of Iran. The initial screening was performed by morphological characteristics on CHROMagar Candida. Each isolate was identified by targeting the D1/D2 rDNA using a multiplex‐PCR method. To validate the mPCR method and determine genetic diversity, the ITS‐rDNA region was randomly sequenced in 40 isolates. Additionally, antifungal susceptibility was evaluated against nine antifungal agents following the CLSI M27‐A4 guidelines. Results All clinical isolates from Iran were identified as N. glabrata. The analysis of ITS‐rDNA sequence data revealed the presence of eight distinct ITS clades and 10 haplotypes among the 40 isolates of N. glabrata. The predominant clades identified were Clades VII, V, and IV, which respectively accounted for 22.5%, 17.5%, and 17.5% isolates. The widest MIC ranges were observed for voriconazole (0.016–8 μg/mL) and isavuconazole (0.016–2 μg/mL), whereas the narrowest ranges were seen with itraconazole and amphotericin B (0.25–2 μg/mL). Conclusion Haplotype diversity can be a valuable approach for studying the genetic diversity, transmission patterns, and epidemiology of the N. glabrata complex.
medical laboratory technology